Loading clinical trials...
Loading clinical trials...
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
iRenix Medical, Inc.
NCT06455384 · Cardiac Conditions, Connective Tissue Diseases, and more
NCT01496625 · Age-Related Macular Degeneration, Diabetic Retinopathy, and more
NCT01432847 · Retinal Disease, AMD, and more
NCT06380075 · Retinal Disease
NCT06789445 · Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), and more
R. Gary Lane, II MD
San Antonio, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions